DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the stock.

Several other research analysts also recently commented on DBVT. HC Wainwright lifted their price objective on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Performance

DBVT stock opened at $4.39 on Tuesday. The company has a market capitalization of $90.30 million, a PE ratio of -0.98 and a beta of 0.67. DBV Technologies has a one year low of $2.20 and a one year high of $9.40. The company’s 50 day moving average price is $3.91 and its two-hundred day moving average price is $3.85.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent reporting period. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.